We are live on ! Find out more
BB

BB Biotech Portfolio holdings

AUM $3.98B
1-Year Est. Return 15.47%
This Fund
S&P 500
This Quarter Est. Return
+8.76%
1 Year Est. Return
+15.47%
3 Year Est. Return
+121.5%
5 Year Est. Return
+265.65%
10 Year Est. Return
–
AUM
$3.27B
AUM Growth
+$215M
Cap. Flow
+$13.1M
Cap. Flow %
0.4%
Top 10 Hldgs %
74.79%
Holding
30
New
–
Increased
16
Reduced
6
Closed
2
Avg Time Held
10.6 quarters
Top 10 Avg Time Held
12 quarters
Top 20 Avg Time Held
10.6 quarters

Top Buys

Rank Stock Value
1
RDUS icon
Radius Health, Inc.
RDUS
+$19M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$14.5M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$11.9M
4
TSRO
TESARO, Inc.
TSRO
+$7.73M
5
HALO icon
Halozyme
HALO
+$6.88M

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$28.4M
2
CELG
Celgene Corp
CELG
+$11M
3
PBYI icon
Puma Biotechnology
PBYI
+$9.14M
4
KITE
Kite Pharma, Inc.
KITE
+$8.16M
5
PTCT icon
PTC Therapeutics
PTCT
+$6.72M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
INCY icon
1
Incyte
INCY
$22.9B
$443M 13.53%
3,514,822
+25,000
+0.7% +$3.18M
2013 Q2
16 quarters
CELG
2
DELISTED
Celgene Corp
CELG
$422M 12.9%
3,249,298
-90,000
-3% -$11M
2013 Q2
16 quarters
IONS icon
3
Ionis Pharmaceuticals
IONS
$7.41B
$374M 11.43%
7,354,095
-107,200
-1% -$4.99M
2013 Q2
16 quarters
RDUS icon
4
DELISTED
Radius Health, Inc.
RDUS
$228M 6.97%
5,038,799
+498,400
+11% +$19M
2014 Q2
12 quarters
GILD icon
5
Gilead Sciences
GILD
$187B
$196M 6%
2,774,596
– –
2013 Q2
16 quarters
VRTX icon
6
Vertex Pharmaceuticals
VRTX
$130B
$190M 5.81%
1,475,445
+20,000
+1% +$2.41M
2013 Q2
16 quarters
ALXN
7
DELISTED
Alexion Pharmaceuticals
ALXN
$165M 5.04%
1,354,428
+125,000
+10% +$14.5M
2013 Q2
16 quarters
NBIX icon
8
Neurocrine Biosciences
NBIX
$14.4B
$159M 4.85%
3,446,552
+245,000
+8% +$11.9M
2013 Q3
15 quarters
AGIO icon
9
Agios Pharmaceuticals
AGIO
$1.87B
$148M 4.51%
2,869,528
+30,000
+1% +$1.53M
2014 Q2
12 quarters
TSRO
10
DELISTED
TESARO, Inc.
TSRO
$123M 3.75%
877,990
+53,408
+6% +$7.73M
2013 Q3
15 quarters
HALO icon
11
Halozyme
HALO
$12.6B
$106M 3.24%
8,265,304
+515,472
+7% +$6.88M
2013 Q2
16 quarters
ALNY icon
12
Alnylam Pharmaceuticals
ALNY
$30.7B
$97.4M 2.98%
1,221,338
-20,000
-2% -$1.28M
2013 Q2
16 quarters
REGN icon
13
Regeneron Pharmaceuticals
REGN
$79B
$88.4M 2.7%
180,000
-65,000
-27% -$28.4M
2013 Q3
15 quarters
SAGE icon
14
DELISTED
Sage Therapeutics
SAGE
$72.3M 2.21%
907,439
-65,000
-7% -$4.7M
2015 Q4
6 quarters
ESPR icon
15
DELISTED
Esperion Therapeutics
ESPR
$70M 2.14%
1,513,542
+105,000
+7% +$3.86M
2015 Q3
7 quarters
KITE
16
DELISTED
Kite Pharma, Inc.
KITE
$66.3M 2.03%
640,000
-100,000
-14% -$8.16M
2015 Q2
8 quarters
JUNO
17
DELISTED
Juno Therapeutics, Inc.
JUNO
$65.3M 2%
2,185,000
– –
2015 Q2
8 quarters
MGNX icon
18
MacroGenics
MGNX
$236M
$41.1M 1.26%
2,350,112
+90,112
+4% +$1.72M
2016 Q2
4 quarters
MYOV
19
DELISTED
Myovant Sciences Ltd.
MYOV
$38.8M 1.19%
3,317,171
+14,336
+0.4% +$178K
2016 Q4
2 quarters
AVXS
20
DELISTED
AveXis, Inc. Common Stock
AVXS
$33.1M 1.01%
402,800
+70,000
+21% +$5.25M
2016 Q3
3 quarters
ICPT
21
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$31M 0.95%
255,719
– –
2015 Q1
9 quarters
ITCI icon
22
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$26.7M 0.82%
2,150,000
+225,000
+12% +$2.61M
2016 Q2
4 quarters
FPRX
23
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$23.4M 0.72%
777,500
+50,000
+7% +$1.56M
2017 Q1
1 quarter
ALDR
24
DELISTED
Alder Biopharmaceuticals
ALDR
$22.2M 0.68%
1,941,008
+255,858
+15% +$4.73M
2015 Q2
8 quarters
PRTA icon
25
Prothena Corp
PRTA
$441M
$18.9M 0.58%
350,000
– –
2015 Q3
7 quarters
1
2

Similar funds

SBAM
Santa Barbara Asset Management Los Angeles, California $6.43B AUM 10.99% 1-Year Est. Return
HFS
HL Financial Services Louisville, Kentucky $6.5B AUM 9.56% 1-Year Est. Return
SA
SQ Advisors Naples, Florida $1.32B AUM 10.3% 1-Year Est. Return
WF
WealthTrust Fairport Cleveland, Ohio $1.06B AUM 3.47% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
AB
AT Bancorp Dubuque, Iowa $823M AUM 0.35% 1-Year Est. Return
MFBTD
MB Financial Bank - Trust Department Rosemont, Illinois $816M AUM 5.49% 1-Year Est. Return

BB Biotech's Q2 2017 Portfolio in Review

As of Q2 2017, BB Biotech held 30 positions worth $3.27B, up 7% from $3.06B the previous quarter. Its ten largest holdings account for 75% of the portfolio.

BB Biotech's Q2 2017 filing shows 16 increased, 6 reduced and 2 closed positions. The largest sale was Regeneron Pharmaceuticals, an estimated $28.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • BB Biotech added most to Radius Health, Inc. in Q2 2017, an estimated $19M increase.
  • BB Biotech's biggest Q2 2017 reduction was Regeneron Pharmaceuticals, cutting an estimated $28.4M.
  • BB Biotech fully exited Puma Biotechnology in Q2 2017, selling an estimated $9.14M.
  • BB Biotech's ten largest holdings make up 75% of its $3.27B portfolio in Q2 2017.
  • BB Biotech opened 0 new positions and closed 2 in Q2 2017.
  • BB Biotech's portfolio value rose 7% quarter-over-quarter to $3.27B.

Based on BB Biotech's 13F filing for Q2 2017, filed 11 Aug 2017.